 1. Patients with age 75 years with CML in first chronic phase, which has failed to achieve a cytogenetic or molecular complete remission or has progressed after imatinib treatment. Criteria for failure are the international consensus criteria Appendix H. Patients intolerant to tyrosine kinase inhibitor therapy are also eligible. 